This is a routine organizational update with no immediate financial or clinical catalyst. Monitor for upcoming clinical trial results or pipeline milestones to assess the impact of the new leadership structure.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals announced executive leadership changes and an operational restructuring, including the appointment of Dr. Jeff Millard as EVP Technical Operations, Dr. Alex Therien assuming leadership of R&D, and the transition of operations from Victoria to Vancouver and Seattle. Amanda Malone stepped down as Chief Scientific and Operating Officer. The filing contains no financial data, clinical updates, or guidance.
Key Facts
- Dr. Jeff Millard appointed EVP Technical Operations effective July 13, 2026.
- Dr. Alex Therien takes helm of R&D as EVP Research & Development.
- Operations transitioned from Victoria to Vancouver and Seattle; CEO and key executives to be based in Seattle.
- Amanda Malone stepped down as Chief Scientific and Operating Officer effective July 10, 2026.
Financial Impact
No financial figures disclosed; no revenue, earnings, or cost impact provided.
Risk Factors
- Departure of Chief Scientific and Operating Officer may cause short-term operational disruption.
- Restructuring and relocation could introduce execution risk in clinical development timelines.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004676 |
| Document: f6k_071526.htm | 0001171843-26-004676 |
| Document: 0001171843-26-004676-index-headers.html | 0001171843-26-004676 |
| Document: 0001171843-26-004676-index.html | 0001171843-26-004676 |
| Document: 0001171843-26-004676.txt | 0001171843-26-004676 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $7.59 | awaiting T+5 | — | $6.85 (−9.75%) |
Oct 15, 2026 11d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $6.85 (+1.18%) |
Oct 9, 2026 17d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $6.85 (−8.18%) |
Sep 30, 2026 26d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Sep 30, 2026 26d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Aug 25, 2026 9w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $6.85 (+7.68%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $6.85 (+2.70%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $6.85 (+5.71%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $6.85 (+5.06%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $6.85 (+3.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers